DGAP-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Forecast Ad-hoc notification in accordance with Sec. 17 of the MAR Drägerwerk AG & Co. KGaA: Preliminary figures for H1 2022: net sales and earnings significantly below prior-year level despite strong order development – full-year guidance confirmed due to expected business recovery in the second half of the year Lübeck, July 14, 2022 – Dräger's net sales decreased to around EUR 1,302 million in the first half of 2022 based on preliminary calculations. Net of currency effects, net sales were thus 22.2 percent below the figure of the prior-year period (6 months 2021: EUR 1,633.4 million). On the one hand, sales could not be realized as quickly due to limited product availability. On the other hand, business was impacted by a lockdown-related sales decline in China. Earnings before interest and taxes (EBIT) decreased to around EUR -112 million (6 months 2021: EUR 209.2 million). The main reasons for this were the decline in sales and the lower gross margin. The gross margin amounted to around 40 percent (6 months 2021: 49.1 percent), mainly due to the change in product mix resulting from the lower demand for corona-related products and higher costs for the purchase of electronic components and logistics. It should be noted that the price increases implemented in the first half of the year will not fully benefit earnings until the second half. Order intake increased by 8.9 percent (net of currency effects) to around EUR 1,648 million (6 months 2021: EUR 1,477.4 million). At the same time, demand for products such as workplace infrastructure, anesthesia devices, respiratory and personal protection products as well as gas detection systems rose in particular. The medical division recorded an increase of 5.9 percent (net of currency effects) to around EUR 997 million (6 months 2021: EUR 914.4 million). The safety division saw growth of 13.8 percent (net of currency effects) to around EUR 651 million (6 months 2021: EUR 563.0 million). In the second quarter, order intake rose by 7.6 percent (net of currency effects) to around EUR 822 million (Q2 2021: EUR 737.6 million) based on preliminary calculations. Net sales decreased by 24.7 percent (net of currency effects) to around EUR 653 million (Q2 2021: EUR 841.3 million). Gross profit margin was around 39 percent (Q2 2021: 46.3 percent). EBIT amounted to around EUR -77 million (Q2 2021: EUR 80.3 million). Based on the high order backlog and an expected improvement of the delivery situation, Dräger expects a significant recovery in business development in the second half of the year. The Executive Board therefore confirms the forecast for the full year 2022. Accordingly, the Board continues to expect a decline in net sales of between -5.0 and -9.0 percent (net of currency effects) and an EBIT margin of between 1.0 and 4.0 percent. It remains likely that the lower end of the range will be achieved in each case. This forecast is made on the assumption that the economic environment will not deteriorate any further. The full results for the first six months of the fiscal year will be published on July 28, 2022.
Drägerwerk AG & Co. KGaA Investor Relations: Corporate Communications:
Disclaimer
14-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Drägerwerk AG & Co. KGaA |
Moislinger Allee 53-55 | |
23558 Lübeck | |
Germany | |
Phone: | +49 (0)451 882-0 |
Fax: | +49 (0)451 882-2080 |
E-mail: | info@draeger.com |
Internet: | www.draeger.com |
ISIN: | DE0005550602, DE 000 555 063 6, DE 000 555 071 9 |
WKN: | 555060, 555063 Vorzüge, 555071 Genussschein D |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart, Tradegate Exchange |
EQS News ID: | 1398455 |
End of Announcement | DGAP News Service |
|
1398455 14-Jul-2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.